JP2004536077A5 - - Google Patents

Download PDF

Info

Publication number
JP2004536077A5
JP2004536077A5 JP2003501483A JP2003501483A JP2004536077A5 JP 2004536077 A5 JP2004536077 A5 JP 2004536077A5 JP 2003501483 A JP2003501483 A JP 2003501483A JP 2003501483 A JP2003501483 A JP 2003501483A JP 2004536077 A5 JP2004536077 A5 JP 2004536077A5
Authority
JP
Japan
Prior art keywords
composition according
polypeptide
sequence
sequence seq
similarity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003501483A
Other languages
English (en)
Japanese (ja)
Other versions
JP4944360B2 (ja
JP2004536077A (ja
Filing date
Publication date
Priority claimed from EP01401537A external-priority patent/EP1262187A1/en
Application filed filed Critical
Priority claimed from PCT/EP2002/006924 external-priority patent/WO2002098444A2/en
Publication of JP2004536077A publication Critical patent/JP2004536077A/ja
Publication of JP2004536077A5 publication Critical patent/JP2004536077A5/ja
Application granted granted Critical
Publication of JP4944360B2 publication Critical patent/JP4944360B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003501483A 2001-05-25 2002-05-24 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 Expired - Fee Related JP4944360B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP01401377.5 2001-05-25
EP01401377 2001-05-25
EP01401537.4 2001-06-14
EP01401537A EP1262187A1 (en) 2001-05-25 2001-06-14 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP02290795 2002-03-29
EP02290795.0 2002-03-29
PCT/EP2002/006924 WO2002098444A2 (en) 2001-05-25 2002-05-24 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009006614A Division JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Division JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Publications (3)

Publication Number Publication Date
JP2004536077A JP2004536077A (ja) 2004-12-02
JP2004536077A5 true JP2004536077A5 (enExample) 2012-01-26
JP4944360B2 JP4944360B2 (ja) 2012-05-30

Family

ID=27224392

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003501483A Expired - Fee Related JP4944360B2 (ja) 2001-05-25 2002-05-24 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2009006614A Expired - Lifetime JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Pending JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用
JP2014090333A Expired - Lifetime JP5847231B2 (ja) 2001-05-25 2014-04-24 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009006614A Expired - Lifetime JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Pending JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用
JP2014090333A Expired - Lifetime JP5847231B2 (ja) 2001-05-25 2014-04-24 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Country Status (12)

Country Link
US (4) US7169758B2 (enExample)
EP (2) EP2186524B1 (enExample)
JP (4) JP4944360B2 (enExample)
CN (2) CN101884780B (enExample)
AT (1) ATE427114T1 (enExample)
AU (1) AU2002321105A1 (enExample)
CA (1) CA2448382C (enExample)
CY (1) CY1120241T1 (enExample)
DE (1) DE60231804D1 (enExample)
ES (2) ES2326469T5 (enExample)
TR (1) TR201806761T4 (enExample)
WO (1) WO2002098444A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2448382C (en) * 2001-05-25 2013-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin as a regulator of iron homeostasis
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
AU2003295644A1 (en) 2002-11-19 2004-07-22 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
DE10349124A1 (de) 2003-10-22 2005-05-19 Roche Diagnostics Gmbh Differenzialdiagnostik mit Hepcidin
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
KR100679100B1 (ko) * 2004-10-29 2007-02-06 엘지.필립스 엘시디 주식회사 수평 전계 인가형 액정 표시 패널 및 그 제조방법
US7968091B2 (en) 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
US8076306B2 (en) * 2006-04-12 2011-12-13 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
MX2009000685A (es) * 2006-07-21 2009-01-30 Amgen Inc Metodo para detectar y/o cuantificar hepcidina en una muestra.
WO2008036933A2 (en) * 2006-09-21 2008-03-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the hamp gene
WO2008047485A1 (en) * 2006-10-17 2008-04-24 Naohisa Tomosugi Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator
AR065083A1 (es) * 2007-02-02 2009-05-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
WO2008124768A1 (en) 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
WO2008146903A1 (ja) * 2007-05-31 2008-12-04 Naohisa Tomosugi 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法
ES2385772T3 (es) 2007-10-02 2012-07-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos específicos para la hepcidina humana
EP2201382A4 (en) 2007-10-26 2011-01-26 Univ Utah Res Found IDENTIFICATION OF THE HEPCIDIN BINDING PLACE OF FERROPORTIN
CL2008003190A1 (es) * 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
US8609817B2 (en) * 2008-08-06 2013-12-17 Eli Lilly And Company Anti-hepcidin-25 selective antibodies and uses thereof
US20100068737A1 (en) * 2008-09-16 2010-03-18 University Of Tennessee Research Foundation Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin
EP2349332B1 (en) * 2008-11-13 2019-10-23 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation bmp-6
US8999935B2 (en) * 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
DE102009034150A1 (de) 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
BR112012003701A2 (pt) 2009-08-20 2019-09-24 Vifor Int Ag "novos antagonistas de quinolina-hepcidina"
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
BR112012005119A2 (pt) 2009-09-07 2016-11-22 Vifor Int Ag novos antagonistas de hepcidina etanodiaminas
AR078278A1 (es) 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
US9228188B2 (en) 2011-06-21 2016-01-05 Alnylam Pharmaceuticals, Inc. Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression
WO2013002354A1 (ja) * 2011-06-29 2013-01-03 株式会社ダナフォーム 生体試料の前処理方法、ｒｎａの検出方法及び前処理キット
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
EP2968503B1 (en) 2013-03-15 2018-08-15 Intrinsic LifeSciences LLC Anti-hepcidin antibodies and uses thereof
EP2976085A1 (en) 2013-03-21 2016-01-27 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
EP3203991A4 (en) 2014-10-10 2018-06-20 The Board of Regents of The University of Texas System Hif-2 inhibitors for treating iron overload disorders
KR20180109917A (ko) * 2016-01-08 2018-10-08 라 졸라 파마슈티칼 컴파니 헵시딘의 투여 방법
WO2018165186A1 (en) * 2017-03-07 2018-09-13 Intrinsic Lifesciences Llc Assessment of chronic iron deficiency
US20190315821A1 (en) * 2018-02-23 2019-10-17 La Jolla Pharmaceutical Company Compositions comprising hepcidin and methods of use thereof
US12011489B2 (en) 2022-03-30 2024-06-18 Christopher Key Compositions and methods for treating inflammatory disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766207B1 (fr) * 1997-07-11 2000-12-08 Rhone Poulenc Agrochimie Gene chimere codant pour la drosomycine, vecteur le contenant pour la transformation des cellules vegetales et plantes transformees obtenues resistantes aux maladies
FR2770853B1 (fr) * 1997-11-07 1999-12-31 Rhone Poulenc Agrochimie Gene codant pour la thanatine, vecteur le contenant et plantes transformees obtenues resistantes aux maladies
US20030190669A1 (en) * 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000056879A1 (en) * 1999-03-22 2000-09-28 Universität Zürich TRANSFORMING GROWTH FACTOR (TFG) β SUPERFAMILY ANTAGONISTS
CA2448382C (en) * 2001-05-25 2013-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin as a regulator of iron homeostasis
US8017737B2 (en) † 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
AU2003295644A1 (en) † 2002-11-19 2004-07-22 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US7968091B2 (en) * 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
PL2061313T3 (pl) * 2006-09-16 2014-01-31 Soy Labs Llc Zastosowanie peptydu sojowego (lunazyny) do obniżania poziomu cholesterolu całkowitego i ldl
AR065083A1 (es) † 2007-02-02 2009-05-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
ES2385772T3 (es) † 2007-10-02 2012-07-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos específicos para la hepcidina humana
WO2009097461A1 (en) 2008-01-29 2009-08-06 Neoguide Systems Inc. Apparatus and methods for automatically controlling an endoscope
WO2010065815A2 (en) † 2008-12-05 2010-06-10 The Regents Of The University Of California Mini-hepcidin peptides and methods of using thereof
BR112014013697A2 (pt) 2011-12-09 2020-11-03 The Regents Of The University Of California peptídeos mini-hepcidina modificados e métodos de uso dos mesmos
AU2015243990A1 (en) 2014-04-07 2016-11-10 La Jolla Pharmaceutical Company Hepcidin mimetic peptides and uses thereof
WO2015200916A2 (en) 2014-06-27 2015-12-30 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof

Similar Documents

Publication Publication Date Title
EP1105422B1 (en) Hepatitis c inhibitor peptides
US6767991B1 (en) Hepatitis C inhibitor peptides
JP4452401B2 (ja) Ｃ型肝炎ウイルス阻害ペプチドアナログ
JP2008522617A5 (enExample)
WO1999007733A2 (en) Hepatitis c inhibitor peptides
JP2004525097A5 (enExample)
JP2008502301A (ja) ペプチドの抱合
JP2007535910A5 (enExample)
JP2004521123A5 (enExample)
JP2012526789A (ja) インターフェロンをｐｅｇで標識する方法
JP2002522508A5 (enExample)
MXPA04005891A (es) Proteinas envolventes del virus de hepatitis c purificadas para diagnostico y uso terapeutico.
JP2007536910A5 (enExample)
JP2011501675A5 (enExample)
JP2007326781A (ja) 抗ｓａｒｓウイルス剤
JP2011515471A5 (enExample)
JP2024516605A5 (enExample)
JPH06220090A (ja) ポリペプチド
WO2002055548A3 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
JP7862685B2 (ja) 新規なｇｌｐ－１、ｇｉｐ、及びグルカゴン受容体の全てに対して活性を有する三重活性体並びにそれを含む肥満の予防又は治療用薬学的組成物
CN101883784B (zh) N-端修饰的干扰素-α
JP2005500390A5 (enExample)
CN1766115A (zh) 肿瘤血管导向肽与人干扰素α－2b的融合蛋白的制备方法
CA2782624C (en) Therapeutic use of protein-polymer conjugates
TW202604565A (zh) 用於預防或治療心血管疾病之三重ｇｌｐ－１／ｇｉｐ／升糖素受體促效劑及包含該促效劑之醫藥組成物